Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
about
Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling NetworksHepatocellular carcinoma: Will novel targeted drugs really impact the next future?Circulating tumor DNA in hepatocellular carcinoma: trends and challengesCombination treatment including targeted therapy for advanced hepatocellular carcinomaA Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma CellsA Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.Brain metastases from hepatocellular carcinoma: recent advances and future avenuesHigh Expression of Retinoblastoma-Binding Protein 2 (RBP2) in Patients with Hepatocellular Carcinoma and Its Prognostic Significance.A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy.Mechanisms of doxorubicin resistance in hepatocellular carcinomaInactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.Epithelial-Mesenchymal Transition is Superior to Vessels-Encapsulate Tumor Cluster in Promoting Metastasis of Hepatocellular Carcinoma: a Morphological Evidence.Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase.Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic areaPyroptosis is involved in the pathogenesis of human hepatocellular carcinoma.The role of liver progenitor cells during liver regeneration, fibrogenesis, and carcinogenesis.Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.Advances in Local and Systemic Therapies for Hepatocellular Cancer.Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors.Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?Promising new strategies for hepatocellular carcinoma.Peretinoin as an adjuvant therapy for hepatocellular carcinoma.Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis.Systemic treatment for hepatocellular carcinoma: Still unmet expectationsTumor regulation of the tissue environment in the liver.TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.Identification of the Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma.Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway.Mass spectral analysis of the multikinase inhibitor BZG and its metabolites and analysis of their binding to vascular endothelial growth factor receptor-2.Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression.Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer.Antitumoral effect of Ocoxin in hepatocellular carcinoma.High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes.Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib.
P2860
Q26741086-79AA7B63-EDAC-4BA4-9118-39BDC6056A10Q26741201-08E915E9-C6A8-4786-AE9A-26C90F6C4D46Q26749417-A6802BB9-BD3C-43C8-8C4E-14C167C3D5A9Q28077738-1A5084F5-9778-499B-996F-4673D82CC781Q28553513-9BAA85C6-1CA3-49E2-8316-EB0A7A312F92Q33442349-618F8F8D-E31C-4080-BF30-13B614017215Q33649050-E5831F1C-DB94-45E7-8EC0-7387FB2720E6Q33792639-64E76A84-AC93-4C40-9995-6432A1476685Q36462972-94B3048E-51C5-4277-A156-EFC86DFE9CB8Q36502944-942F64E3-0338-4773-9745-820C1754ECBBQ36687760-0889911E-C7B2-4B21-AB1F-A92AE22C053AQ37141152-F70ECF89-17A8-448D-B2E4-3A2709841F75Q37604305-B55FBFD2-9982-4101-B4DD-A5202CD2D635Q37662305-F64708BE-A236-45F7-A7EB-98DE084C0463Q37699304-E5B652E1-55B7-433E-B290-CFE0B65B5E7FQ37708998-440234B5-0E5A-4FD5-BFDB-216B5D15108DQ38647996-FF3E4873-CD6F-4603-8C61-D9866D7B7C1BQ38686609-156B69DB-B2C4-4779-AC33-2C5C13CB313DQ38697243-4C02C430-D2C6-4265-A351-39ECB8629405Q38726039-2CB672A8-901F-495C-8696-58413C8FB7DFQ38806090-69C93EE9-DFB4-42AF-9613-929A719E9D21Q38824017-917BE96A-4E4D-4F52-A759-140CDB47590AQ38933836-E2167E9E-EB2F-4001-BD32-F445CEB3422AQ38936589-27028EEA-A5D2-46E1-8AA4-A4EF9E19B125Q38959682-FFCE2292-6B28-494B-A6DC-EF0F1B82DA18Q38974653-3F8E570E-AA62-4AAA-88EF-38003B3E04C7Q39112745-EAD396DA-018A-41C9-B2C7-854D19C5B4D8Q39123136-1F0B721B-7036-4C93-A74C-3FCAF36DA679Q39175089-9C84CD9D-89F5-4BBC-8C9D-A8A041076EA4Q39307416-35408385-E84C-4E10-874D-007A0E9DDCCDQ39366121-746808C1-C0FE-42EC-A4E9-84B8DBFCE122Q39499017-61C5084F-790A-4B95-A579-9032B114F902Q40070808-123452F6-AEF0-4B08-8E53-7BD07A9A2855Q40107969-A0F48DB7-9030-4FF5-A1CA-F6956AFC6948Q40248432-6EC78885-AB0C-4E2E-81D3-7158F02D8006Q40955279-C06FADE1-DBD1-4EA9-9C0D-CF75111DC96CQ41116584-8E4B3A99-673F-4250-8BA4-39B97FFF4E53Q41145089-3EE606B9-3F40-4E42-9BBC-C732D9E34FFBQ41413012-D5FC43EE-8156-4559-8F34-8BE738A01481Q41438778-4041040B-4C0B-4D03-9A6B-E67685814BD3
P2860
Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
@en
type
label
Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
@en
prefLabel
Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
@en
P2860
P1476
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
@en
P2093
Anja Lachenmayer
Richard S Finn
P2860
P304
P356
10.1038/NRCLINONC.2015.103
P407
P577
2015-06-09T00:00:00Z